Minnesota Clinical Research Hub (MCRH) announced its first contract for a multi-site, phase I clinical research study. The contract was awarded to Prism Research and MD Biosciences, both based in St. Paul, Minnesota, and two of MCRH’s founding members.
Prism and MD Biosciences will provide comprehensive clinical trial execution and management, central laboratory services and biomarker testing to a leading European plasma biotherapeutics company seeking to obtain FDA approval for a vaccine currently available in Europe.
MCRH is a partnership of five Minnesota health industry leaders, collaborating to provide a comprehensive clinical trial platform, making it easier for life science companies and clinicians to bring lifesaving and life improving products to patients in need. In concert with local clinicians, Prism Research, MD Biosciences, Center for Diagnostic Imaging, Medtronic and ThreeWire provide sponsors with a seamless, customizable, yet flexible platform for conducting clinical trials.
“Minnesota has always possessed the critical assets required to be a significant contributor in pharmaceutical development,” said Geoff Grassle, MCRH Partner. “This contract will be the first of many opportunities for MCRH partners to leverage the expertise of local clinicians and MCRH members to expand Minnesota’s recognition as an international destination for clinical innovation.”
About Prism Research: Prism Research is a 52-bed clinical research company specializing in the execution and management of phase I/IIa studies in patient and healthy populations with an emphasis on complex study designs. Since 2005, Prism Research has provided FDA approved investigational pharmaceutical and medical device testing services for drug and device manufacturers, academic institutions and private physicians as well as other researchers across Minnesota, the U.S. and abroad.